Abstract:Background: The management of clinical heart failure with a preserved ejection fraction (HFpEF) is often complicated by concurrent renal dysfunction, known as the cardiorenal syndrome. This, combined with the notable lack of evidence-based therapies for HFpEF, highlights the importance of examining mechanisms and targetable pathways in HFpEF with the cardiorenal syndrome. Methods: HFpEF was induced in mice by uninephrectomy, infusion of d-aldosterone (HFpEF; N=10) or saline (Sham; N=8), and given 1% NaCl drinking water for 4 weeks. Renal fibrosis and endothelial-mesenchymal transition (endo-MT) were evident once HFpEF developed. Human aortic endothelial cells were treated for 4 days with 10% serum obtained from patients with chronically stable HFpEF with the cardiorenal syndrome (N=12) and compared with serum-treated human aortic endothelial cells from control subjects (no cardiac/renal disease; N=12) to recapitulate the in vivo findings. Results: Kidneys from HFpEF mice demonstrated hypertrophy, interstitial fibrosis (1.9-fold increase; P<0.05) with increased expression of endo-MT transcripts, including pdgfrβ (platelet-derived growth factor receptor β), snail, fibronectin, fsp1 (fibroblast-specific protein 1), and vimentin by 1.7- (P=0.004), 1.7- (P=0.05), 1.8- (P=0.005), 2.6- (P=0.001), and 2.0-fold (P=0.001) versus Sham. Immunostaining demonstrated co-localization of CD31 and ACTA2 (actin α2) in kidney sections suggesting evidence of endo-MT. Similar to the findings in HFpEF mice, comparable endo-MT markers were also significantly elevated in human aortic endothelial cells treated with serum from patients with HFpEF compared with human aortic endothelial cells treated with serum from control subjects. Conclusions: These translational findings demonstrate a plausible role for endo-MT in HFpEF with cardiorenal syndrome and may have therapeutic implications in drug development for patients with HFpEF and concomitant renal dysfunction.

Endothelial to mesenchymal transition in cardiovascular diseases: Developmental signalling pathways gone awry.

Endothelial-to-Mesenchymal Transition in Cardiovascular Pathophysiology

In Brief: Endothelial-To-Mesenchymal Transition

TGF-β-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering

Endothelial-to-mesenchymal Transition: A Novel Therapeutic Target for Cardiovascular Diseases

The Role of Endothelial-to-Mesenchymal Transition in Cardiovascular Disease

Endothelial-to-mesenchymal transition: Pathogenesis and therapeutic targets for chronic pulmonary and vascular diseases

Acetate Controls Endothelial-to-mesenchymal Transition

The Therapeutic Potential of Targeting the Endothelial-to-mesenchymal Transition

The Role of Endothelial–mesenchymal Transition in Development and Pathological Process

TGF-β-mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing.

TGF--mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing

TGF-&#946;-mediated Endothelial to Mesenchymal Transition (endmt) and the Functional Assessment of EndMT Effectors Using CRISPR/Cas9 Gene Editing

Endothelial to Mesenchymal Transition in Pulmonary Vascular Diseases

Endothelial-to-mesenchymal transition: New insights into vascular calcification

Research progress of endothelial-to-mesenchymal transition

TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases

Transforming Growth Factor β–Induced Endothelial-to-Mesenchymal Transition: A Switch to Cardiac Fibrosis?

EndMT: A promising and controversial field

Endothelial Mesenchymal Transition in Cardiac Fibrosis

Endothelial-Mesenchymal Transition in Heart Failure With a Preserved Ejection Fraction: Insights Into the Cardiorenal Syndrome